Dexcom Q2 FY26 GAAP net income rises 39% to $249.1 million; revenue climbs 13% to $1.31 billion
Reuters2026/07/30 20:12- DexCom posted Q2 revenue of USD 1.31 billion, up 13% year over year, with U.S. revenue up 11% and international up 19%.
- GAAP operating income climbed to USD 318.3 million, lifting operating margin to 24.3% from 18.4% a year earlier.
- GAAP net income rose to USD 249.1 million, or USD 0.64 per diluted share.
- Non-GAAP operating income increased to USD 328.3 million, taking non-GAAP operating margin to 25.1% from 19.2%.
- Raised 2026 revenue guidance to USD 5.18-5.25 billion; highlighted positive CONNECT trial results and a reimagined Stelo app with AI-driven insights.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Endeavour Silver suspends Terronera mine operations after illegal blockade in Mexico
Kuraray releases transcript of Q2 FY2026 earnings Q&A session
"Even with money, it's unattainable"! Supply-demand imbalance intensifies, indium phosphide experiences the largest price surge in history
The explosive growth in demand for AI computing power has led to a severe shortage of indium phosphide (InP) substrates and epitaxial wafers, with prices in the fourth quarter expected to surge by more than 10%, marking the largest single increase in history. Prices have already been raised several times consecutively. Bottlenecks in upstream substrate production capacity are difficult to resolve quickly, making the supply-demand imbalance hard to address in the short term. Suppliers have stated bluntly that even if buyers are willing to pay a premium, inventory may still not be available.
Crypto prices
More
